Is Incyte’s tafasitamab regimen strong enough to challenge first-line DLBCL standards?
Find out how Incyte’s tafasitamab data could reshape first-line high-risk DLBCL treatment after frontMIND’s EHA 2026 readout.
Pharma & Biotech